Skip to main content

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Recruiting · Phase 3 · NCT05943535

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease

At a glance

Research payments reported, 2025
$3.2M
U.S. investigators named
67
Sites paid
63
Planned or actual enrollment
698

About the trial

Sponsor
United Therapeutics
Tested
Placebo (drug), Inhaled Treprostinil (drug), Treprostinil Ultrasonic Nebulizer (device)
Dates
Started 2023-10-30; completion 2027-11
Results posted
Not yet

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

From ClinicalTrials.gov, last updated 2026-07-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $3.2M in research payments for this study in 2025 (798 payments).

Products named: Tyvaso

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.